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Abstract
Background: Multifactor Dimensionality Reduction (MDR) has been widely applied
to detect gene-gene (GxG) interactions associated with complex diseases. Existing
MDR methods summarize disease risk by a dichotomous predisposing model
(high-risk/low-risk) from one optimal GxG interaction, which does not take the
accumulated effects from multiple GxG interactions into account.
Results: We propose an Aggregated-Multifactor Dimensionality Reduction (A-MDR)
method that exhaustively searches for and detects significant GxG interactions to
generate an epistasis enriched gene network. An aggregated epistasis enriched risk
score, which takes into account multiple GxG interactions simultaneously, replaces
the dichotomous predisposing risk variable and provides higher resolution in the
quantification of disease susceptibility. We evaluate this new A-MDR approach in a
broad range of simulations. Also, we present the results of an application of the
A-MDR method to a data set derived from Juvenile Idiopathic Arthritis patients
treated with methotrexate (MTX) that revealed several GxG interactions in the folate
pathway that were associated with treatment response. The epistasis enriched risk
score that pooled information from 82 significant GxG interactions distinguished
MTX responders from non-responders with 82% accuracy.
Conclusions: The proposed A-MDR is innovative in the MDR framework to
investigate aggregated effects among GxG interactions. New measures (pOR, pRR
and pChi) are proposed to detect multiple GxG interactions.
Keywords: A-MDR, Epistasis enriched risk score, Epistasis enriched gene network,
pRR, pOR, pChi
Background
Human diseases usually have complex inheritance patterns, and single nucleotide poly-
morphisms (SNPs) has been utilized to explain the variation in susceptibility to many
common complex diseases as well as the response to drug therapy. The advancement
of genotyping technology has made genotypic data readily accessible to investigators at
low cost. However, many challenges remain with regard to identifying genes that ren-
der people susceptible to non-Mendelian disorders and in understanding the associa-
tions and functional relationships among genes. More and more, researchers have been
advocating for advanced statistical analysis to quantify complex and interactive bio-
logical and genetic relationships [1,2].
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Multifactor Dimensionality Reduction (MDR) is a statistical paradigm for characterizing
and detecting nonlinear complex gene-to-gene interactions (epistasis) possibly associated
with susceptibility to disease [3]. When numerous genes are involved in a complex canon-
ical pathway or network, traditional approaches for data analysis, such as a Chi-square test
or Fisher’s exact test, might not detect the associations between risk factors and outcomes
since these approaches assess only marginal main effects of the identified risk factors. Al-
though one can employ logistic regression or other standard multivariate categorical data
analysis approaches to explore interactions among SNPs, there are an enormous number of
possible interactions in a model with both linear and nonlinear effects. Consequently, stand-
ard multivariate categorical data analysis approaches might detect very few interactions, and
even then the cost in terms of sample size might be immense. MDR addresses these difficul-
ties by converting high-dimensional genotypic data into a single predictive variable. Geno-
typic combinations are used to define high risk and low risk strata for the one-dimensional
predisposing risk factor. MDR can reveal non-linear epistasis at a moderate sample size with
no requirements on the underlying distributions of genotypes or outcomes [4].
The most commonly used MDR approach is described in detail by Ritchie et al. [3]. To
distinguish this method from its various extensions, we will refer to it as the original MDR
method. Related statistical software has been developed by Hahn et al. [4], Bush et al. [5],
Winham and Motsinger-Reif [6], and Moore and colleagues (www.epistasis.org). In general,
the MDR process can also be combined with a filter preprocess step by first applying global
testing and filtration techniques to select the optimal number of SNPs for MDR analysis by
searching for a subset of genes likely to interact with other genes using the ReliefF filtering
process [7,8].
Details of the MDR [3] are briefly described here. MDR performs an exhaustive search of
all variables and variable combinations to identify univariate or multivariate disease risk
models. For each locus or multi-locus combination, attribute construction is performed to
make a single variable with two categories: high risk and low-risk. A genotype or combin-
ation of genotypes is assigned high risk status if the ratio of affected subjects to unaffected
subjects exceeds a pre-determined threshold, and low-risk otherwise. This step consolidates
the high-dimensional risk space into a one-dimensional predictive variable. Typically, a 5-
fold or 10- fold cross-validation procedure is employed, beginning with the random division
of the original data set into five or ten subsets of approximately equal sizes [9]. For 10-fold
cross-validation, a model is fit using nine of the ten subsets (collectively referred to as train-
ing data), and then the model is applied to classify observations in both the training data
and the tenth subset not used to fit the model (referred to as validation data). This entire
process is repeated ten times, with one of the ten subsets acting as the validation data [10].
The model’s training accuracy and testing accuracy are defined as the percentage of correct
classifications in the corresponding data sets. The optimal one-locus, two-locus, and three-
locus MDR models with the highest testing accuracy are identified. A one-locus model esti-
mates the main effect of each SNP, while multi-locus models investigate the interactions
among relevant SNPs. The cross validation consistency (CVC) is the number of times in a
10-fold cross validation that a particular multifactorial combination is identified as an opti-
mal model for the training data. Finally, statistical significance of the optimal models is
assessed by 1000- or 10000-count permutation testing [11].
MDR has been applied to identify gene-gene interactions conferring susceptibility to
common diseases, including hypertension [12], bladder cancer [13], Type 2 diabetes [14],
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and rheumatoid arthritis [15,16]. Several extensions of the MDR method have been pro-
posed. These methods entail the use of odds ratios [17], log-linear methods [18], general-
ized linear models [19], methods for data highly imbalanced with the disease outcome
[20], model-based methods [21], contingency table measures of classification accuracy
[22] and familial data [23,24].
In the present work, we propose an Aggregated-Multifactor Dimensionality Reduction
(A-MDR) method that exhaustively searches for statistically significant gene-gene (GxG)
interactions to generate a gene interaction network. In particular, an epistasis enriched
risk score replaces the traditional dichotomous predisposing risk factor in quantifying the
degree of susceptibility to a disease. We also introduce and compare new GxG interaction
measures (pOR, pRR and pChi). An adjustment for multiple comparisons is implemented
to limit false positive discoveries. In the current study we introduce the new approach,
evaluate its performance in a range of simulations, and apply it to a real dataset from Ju-
venile Idiopathic Arthritis patients treated with methotrexate (MTX).
Method
The A-MDR method proposed herein can be applied to detect interactions among alleles,
genotypes, and other categorical explanatory variables. Without loss of generality, we
present the A-MDR method for SNPs with three common states (0 - homozygous refer-
ence, 1 - heterozygous, 2 - homozygous variant). The steps of the A-MDR are outlined in
Figure 1.
Detect multiple GxG interactions using the pOR, pRR or pChi test
The starting point for the A-MDR method is the construction of a predisposing risk
factor. Suppose we want to investigate k–way GxG interactions among M SNPs. For one
particular k–way GxG interaction, there are 3k (SNP(1) = 0, 1, 2 × SNP(2) = 0, 1, 2 × ⋯ ×
SNP(k) = 0, 1, 2) different genotypic combinations. Denote these 3
k genotypic combina-
tions as Cij where j = 1, 2, ⋯, 3
k stands for different genotypic combinations within one
k–way GxG interaction. We need another subscript i ¼ 1; 2;⋯; M
k
 
to cover all k–way
GxG interactions among M SNPs. Let Xij and Yij be the numbers of affected (Test) and un-
affected (Control) subjects in the jth genotypic combination of the ith k–way GxG inter-
action. Let pi0 ¼
X3k
j¼1
Xij
 !
=
X3k
j¼1
Xij þ
X3k
j¼1
Yij
 !
∈ 0; 1ð Þ be the threshold for disease
risk above which a person is deemed highly susceptible using a Naïve Bayes clas-
sifier [25]. Genotypic combinations are then classified into high-risk predisposing
risk groups and low-risk predisposing risk groups, n11,n12,n21,n22, in Table 1
where I{·} denotes an indicator function.
We propose to perform one of the following measures to assess the ith k–way GxG inter-
action (the subscript i is omitted for n’s and e’s):
(a) the predisposing odds ratio (pOR),
pORi ¼ n11n22= n12n21ð ÞF10 F n11n22= n12n21ð Þð Þð Þ
; ð1Þ
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(b) the predisposing relative risk (pRR),
pRRi ¼
n11= n11þn12ð Þ
n21= n21þn22ð Þ
F10 F
n11= n11þn12ð Þ
n21= n21þn22ð Þ
  ; ð2Þ
and
(c) the predisposing chi-square (pChi) test statistic,
Test all −k way GxG interactions among M SNPs.
Perform pOR, pRR or pChi test to assess the significance of each −k way 
GxG interaction using 95% CI and p-value. See Formula 1-3.
The significant GxG interactions used to define the epistasis enriched risk 
score are collectively referred to as an epistasis enriched network. See 
Figure 2A.
For the thn subject, we assign 1 if the thn subject carries a high
predisposing risk genotypic combination and assign 0 if the thn subject 
carries a low risk genotypic combination. See Formula 4.
The risk score will be aggregated (added) together over all k-way GxG 
interactions for each subject. Higher score indicates that a subject carries 
more high risk genotypic combinations. See Formula 4.
The AUC under ROC curve provides an overall evaluation of the epistasis 
enriched risk score’s ability to predict disease risk. The final epistasis 
enriched risk score will be generated based on GxG interactions passing the 
p-value (or FDR) hurdle α̂ that maximizes the AUC of ROC curves. See 
Formula 5.
Non-significant GxG interactions will be removed from further analysis. P-
values may be adjusted by multiplicity algorithms (i.e. FDR).     
Finally, the epistasis enriched risk score, ),( nkR , is treated as a diagnostic 
test for the disease. See Figure 2B.
Figure 1 Flow chart of Aggregated-Multifactor Dimensionality Reduction (A-MDR).
Table 1 2x2 Predisposing risk table (Subscript i is omitted for n’s.)
Case Control Total
High Predisposing Risk
n11 ¼
X3k
j¼1
Xij I
Xij
Xij þ Yij > pi0
 
n12 ¼
X3k
j¼1
Yij I
Xij
Xij þ Yij > pi0
  n1+
Low Predisposing Risk
n21 ¼
X3k
j¼1
Xij I
Xij
Xij þ Yij ≤pi0
 
n22 ¼
X3k
j¼1
Yij I
Xij
Xij þ Yij ≤pi0
  n2+
Total n+1 n+2 N
Dai et al. BioData Mining 2013, 6:1 Page 4 of 16
http://www.biodatamining.org/content/6/1/1
pChii ¼
X2
s¼1
X2
t¼1
nst  estð Þ2
est
F10 F
X2
s¼1
X2
t¼1
nst  estð Þ2
est
 ! ; ð3Þ
where est ¼ nsþnþtN is the expected number of subjects in predisposing risk stratum s
(1 = high predisposing risk, 2 = low predisposing risk) and disease stratum t (1 = Case,
2 = Control) under a null hypothesis of no association between the predisposing risk fac-
tor and the disease. Details of F and F0, along with permutation tests and 95% confidence
intervals for pOR, pRR and pChi are in Appendix I.
Aggregate high risk from significant GxG interactions into risk scores
Assume a study investigates a total of N subjects. For the nth (n = 1, 2, ⋯, N) subject,
an aggregated k–way epistasis enriched risk score, R(k,n), is defined by
R k; nð Þ ¼
X
M
k
 
i¼1
I Pvaluei < α̂f g
X3k
j¼1
I n∈Cij
 	
I Xij= Xij þ Yij

 
> pi0
 	
 " #
8>><
>>:
ð4Þ
α̂ ¼ argmax
0≤α≤0:05
AUC αj gf

ð5Þ
In equation (4), we use the indicator variable, I Pvaluei < α̂f g, to remove the ith non-
significant GxG interaction from further calculation of risk scores. For the remaining
significant GxG interactions, the indicator function, I{n ∈ Cij}I{Xij/(Xij + Yij) > pi0},
assigns 1 if the nth subject carries a high predisposing risk genotypic combination and 0
if the nth subject carries a low predisposing risk genotypic combination. More specific-
ally, I{Xij/(Xij + Yij) > pi0} indicates whether the j
th genotypic combination has high pre-
disposing risk and I{n ∈ Cij} checks whether the n
th subject carries the jth genotypic
combination. Each subject’s risk scores are then summed over all 3kgenotypic combina-
tions and all k–way GxG interactions to obtain an aggregated k–way epistasis enriched
risk score, R(k,n), for the nth subject.
Finally, the epistasis enriched risk score, R(k,n), is treated as a diagnostic test for the
disease. One can consider adding up the predisposing scores with p < 0.05 from these
interactions. Our experience has been that, in many cases, α=0.05 is an arbitrary cutoff
for p-values and some GxG interactions with p-value < 0.05 might have low predictive
ability. Therefore, a receiver operating characteristic (ROC) curve is constructed, and
the area under the ROC curve (AUC) provides an overall evaluation of the epistasis
enriched risk score’s ability to predict disease susceptibility. Instead of using an arbi-
trary cutoff α=0.05, we propose to select α̂ that maximizes the AUC of ROC curves.
Choosing α̂ ¼ argmax
0≤α≤0:05
AUC αj gf for α̂≤0:05 may help focusing on a modest number
of summands that are most conducive to correct classification (arising from the stron-
gest GxG interactions), rather than diluting the epistasis enriched risk score R(k,n) by a
large number of summands that are not as conducive to correct classification (arising
from comparatively weaker GxG interactions).
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Construct multiple GxG interactions into an epistasis enriched network
The significant GxG interactions used to define the epistasis enriched risk score are
collectively referred to as an epistasis enriched network (Figure 2A). Genes involved in
one or more significant interactions appear as nodes in a radial graph. Pairs of genes shar-
ing significant interactions are connected by lines. Each line is labeled with the corre-
sponding pOR, and the line thickness may be chosen to accentuate the strongest pORs.
In summary, the A-MDR method has not only replaced the dichotomous predispos-
ing risk factor with a continuous predictive variable, R(k,n), but has done so by integrat-
ing numerous significant GxG interactions into an epistasis enriched network that may
more adequately explain the susceptibility to complex diseases. Epistasis enriched risk
scores may also be accumulated over GxG interactions from multiple dimensions. For
instance, we can accumulate both two-way and three-way GxG interactions. Or further
consider accumulating one way main effects and up to k–way GxG interactions. The
feasibility of these extensions needs to be assessed by future studies.
Empirical assessment
Extensive Monte Carlo simulations were performed to assess the performance of
pOR, pRR and pChi and compare them to the original MDR in unrelated case–
control studies. To avoid subjective selections of models in favor of our methods,
we report the power and type I error simulation similar to the models previously
assessed by [26]. In each model, we simulated five SNPs with common homozygote
(AA), heterozygote (Aa) and rare homozygote (aa). The minor allele frequencies
(MAF) in each model were set to be 0.5 and 0.25 respectively and the genotypes
were generated according to proportional expectations under Hardy-Weinberg
equilibrium and linkage equilibrium. Equal numbers of affected and unaffected sub-
jects were generated based on penetrance functions given in Table 2. Let D=1 indi-
cate the onset of disease and l1,l2.....,l5 stand for five loci, Pl1×l2 and Pl4×l5 be
penetrance functions from loci 1x2 and loci 4x5 respectively as listed in Table 2.
Our simulations comprised three major scenarios:
Figure 2 Panel A: gene-gene interaction network of 7 SNPs associated with susceptibility to active
arthritis. Significant GxG interactions (FDR<0.05) are connected by line, and the strength of interaction is
labeled with pOR. A larger pOR indicates a stronger interaction (thicker line) while a smaller pOR value
indicates a relatively milder interaction (thinner lines). Panel B: ROC curve for risk scores derived from 82
significant two-locus interactions pooled from 34 SNPs. The risk score is significantly higher in patients with
a poor response to MTX (active arthritis; inset).
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A) Existence of only one two-way interaction in loci 1x2 associated with disease
susceptibility while the remaining loci were unrelated to the outcome variable, i.e.
P(D = 1|l1, l2) = pl1 × l2.
B) Genetic heterogeneity models where a proportion of affected subjects are linked with
interactions between loci 1 and 2 and the rest of affected subjects are linked with
interactions between loci 4 and 5, i.e.
PðD ¼ 1;C l1; l2; l4; l5j Þ ¼ PðD ¼ 1 l1; l2; l4; l5;C ¼ 0j Þ  P C ¼ 0ð Þ
þPðD ¼ 1 l1; l2; l4; l5;C ¼ 1j Þ  PðC ¼ 1Þ ¼ PðD ¼ 1 l1; l2j Þ  P C ¼ 0ð Þ
þP D ¼ 1 l4; l5j Þ  P C ¼ 1ð Þ ¼ γ1pl1l2 þ γ2pl4l5ð
where γ1≥0,γ2≥0 and γ1+γ2=1. The latent binary variable C labels the source of genetic vari-
ation where C=0 indicates that disease is related to loci 1x2 with P(C=0)=γ1 and C=1 indi-
cates that disease is related to loci 4x5 with P(C=1)=γ2. In this study, we consider balanced
genetic heterogeneity models with γ1=γ2=0.5 and unbalanced genetic heterogeneity models
with γ1=0.7 and γ2=0.3.
C) Additive models with two pairs of loci jointly contributing to disease susceptibility. Let
Dl1×l2=1 denote the onset of disease due to the penetrance Pl1×l2 from loci 1*2 and Dl4×l5=1
due to the penetrance Pl4×l5 from loci 4*5. The susceptibility function is given by
P D ¼ 1ð jl1; l2; l4; l5 Þ ¼ Pð Dl1xl2 ¼ 1ð Þ [ Dl4xl5 ¼ 1ð Þ l1; l2; l4; l5j Þ ¼ PðDl1xl2 ¼ 1 l1; l2; l4; l5j Þ
þPðDl4xl5 ¼ 1 l1; l2; l4; l5j Þ  Pð Dl1xl2 ¼ 1ð Þ \ Dl4xl5 ¼ 1ð Þ l1; l2; l4; l5j Þ
¼ PðDl1xl2 ¼ 1 l1; l2j Þ þ PðDl4xl5 ¼ 1 l4; l5j Þ  PðDl1xl2 ¼ 1 l1; l2j Þ
PðDl4xl5 ¼ 1 l4; l5j Þ ¼ pl1l2 þ pl4l5  pl1l2pl4l5
To assess the power of the A-MDR method, we randomly generated 100 sets of data in
the above described scenarios and performed the MDR and A-MDR tests for each random
sample. The power is the percentage of rejection of null hypothesis for the loci with a GxG
interaction. Type I error is the percentage of rejection of null hypothesis when the simulated
loci have no GxG interaction.
Table 2 Simulated gene-gene interaction models with varying penetrance functions and
minor allele frequencies
Model 1 Model 2
BB Bb bb BB Bb bb
AA 0 0.1 0 AA 0 0 0.1
Aa 0.1 0 0.1 Aa 0 0.05 0
aa 0 0.1 0 aa 0.1 0 0
(A) MAF=0.5 (B) MAF=0.5
Model 3 Model 4
BB Bb bb BB Bb bb
AA 0.08 0.07 0.05 AA 0.09 0.05 0.02
Aa 0.1 0 0.1 Aa 0.08 0.09 0.01
aa 0.03 0.1 0.04 aa 0.03 0.01 0.03
(C) MAF=0.25 (D) MAF=0.25
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As shown in Table 3, the Type I errors of all tests were under the nominal rate
of 5%. When only loci 1 and 2 had an interaction (Table 3A), all five measures
had strong power to detect GxG interactions in most models except that the
power of MDR dropped to 0.46 in model 3 with n=300, which could be enhanced
by increasing sample size. We next simulated genetic heterogeneity (Table 3B) with
0.5/0.5, 0.7/0.3 proportions of subjects affected by a mixture model of epistasis
from loci 1x2 and loci 4*5. We noticed that MDR lost power to detect interactions
with weaker effects. The power was not recovered with increased sample sizes. We
last examined the additive models (Table 3C) where susceptibility increases jointly
through loci 1x2 and loci 4x5. MDR has low power to detect both pairs of GxG
interactions. All this evidence suggests that the proposed A-MDR might be a better
choice for detecting complex GxG interactions, especially when multiple GxG
interactions are cumulatively contributing to a phenotype.
Table 3 Power and type I error assessment
A) Only Locus1*2
has an interaction
Model 1 (n=300) Model 2 (n=300) Model 3 (n=300) Model 4 (n=300)
Power Type I Power Type I Power Type I Power Type I
A-MDR pOR 1 0.01 1 0.01 0.75 0.01 1 0.03
A-MDR pRR 1 0 1 0.01 0.71 0.01 1 0.03
A-MDR pChi 1 0.01 1 0 0.86 0.03 1 0
MDR 1 0 1 0 0.46 0.02 1 0
A) Only Locus1*2
has an interaction
Model 1 (n=400) Model 2 (n=400) Model 3 (n=400) Model 4 (n=400)
Power Type I Power Type I Power Type I Power Type I
A-MDR pOR 1 0 1 0 0.86 0 1 0.02
A-MDR pRR 1 0 1 0 0.87 0 1 0.03
A-MDR pChi 1 0.02 1 0.01 0.95 0.01 1 0.02
MDR 1 0 1 0 0.68 0.01 1 0
B) Genetic heterogeneity
γ1=γ2=0.5
Model
1
Model
2
Model
1
Model
2
Model
3
Model
4
Model
3
Model
4
n=400 Power n=800 Power n=400 Power n=800 Power
A-MDR pOR 0.98 1 1 1 0.37 0.91 0.7 1
A-MDR pRR 0.99 1 1 1 0.35 0.78 0.68 1
A-MDR pChi 0.99 1 1 1 0.31 0.99 0.72 1
MDR 0.12 0.75 0.08 0.78 0 0.69 0 0.92
B) Genetic heterogeneity
γ1=0.7,γ2=0.3
Model 1 Model 2 Model 1 Model 2 Model 3 Model 4 Model 3 Model 4
n=400 Power n=800 Power n=400 Power n=800 Power
A-MDR pOR 1 0.35 1 0.98 0.55 0.35 0.92 0.78
A-MDR pRR 1 0.25 1 0.97 0.55 0.3 0.91 0.74
A-MDR pChi 1 0.5 1 0.99 0.6 0.49 0.96 0.86
MDR 1 0 0.99 0 0.14 0.21 0.14 0.38
C) Additive Models Model 1 Model 2 Model 1 Model 2 Model 3 Model 4 Model 3 Model 4
n=400 Power n=800 Power n=400 Power n=800 Power
A-MDR pOR 1 0.72 1 1 0.6 0.16 0.93 0.61
A-MDR pRR 1 0.69 1 0.98 0.61 0.14 0.91 0.55
A-MDR pChi 1 0.79 1 1 0.71 0.29 0.98 0.76
MDR 0.91 0.02 0.99 0.01 0.26 0.14 0.43 0.12
(Within each cell, loci 1x2 is listed in the first column and loci 4x5 is in the second column).
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Application to genotyping data
Juvenile Idiopathic Arthritis (JIA) is one of the most common chronic diseases of child-
hood, affecting an estimated 300,000 children in the U.S. alone, and is an important
cause of morbidity and disability in children. Although methotrexate (MTX) is the
most commonly used second-line anti-inflammatory agent used to treat JIA worldwide,
this antifolate prodrug has shown considerable inter-individual variability in clinical re-
sponse and adverse reactions. Thus far, variables investigated as potential useful predic-
tors of response and toxicity in patients taking MTX, which is used alone and as an
“anchor drug” for many rheumatic conditions, have not been clearly associated with
outcomes. The effect of individual genetic SNP variation within the folate pathway
upon MTX response has been investigated in several studies in adult rheumatoid arth-
ritis (RA) and a few studies in JIA with conflicting results. To elucidate the genetic
architecture impacting the efficacy of MTX, 34 SNPs from 19 folate pathway genes
were measured in 104 subjects. Response-defined as the absence of active arthritis
(swelling not due to bony enlargement or, if no swelling was present, limitation of mo-
tion accompanied by either pain on motion or tenderness, not due to trauma or
explained by prior joint damage [27]-was determined for these subjects. Information
pertaining to the 34 SNPs is listed in Table 4; demographic and clinical characteristics
of the subjects were described by Becker and colleagues [15]. After being on a stable
dose and route of MTX for at least 3 months, 56.7% of the patients (59 out of 104) still
had at least 1 active (i.e., swollen or tender) joint. The presence of active arthritis was
the outcome variable, and represented an incomplete response to MTX. By definition,
the absence of active arthritis-no joint involvement-was considered a positive response
to MTX treatment.
Standard logistic regression analysis did not identify significant main effects from SNPs
or GxG interactions. This could primarily due to the complex and non-linear interactions
among SNPs. For the rest article, the A-MDR and original MDR methods were applied to
the MTX data to search for genetic predictors of response to MTX. Redundant SNPs and
SNPs with no prediction of the phenotype were removed by the ReliefF algorithm [7]. A
complete set of 34 SNPs and 7 filtered SNPs were analyzed respectively.
The original MDR analysis method was applied to obtain the one-locus, two-locus,
and three-locus models with the highest validation accuracy in the original MDR. Two-
locus interactions between genes ATIC and MTHFD2 were significant in testing accur-
acy but not in CVC. The prediction accuracy from the optimal MDR model was 75%.
We then utilized pOR, pRR, and pChi to identify and characterize GxG interactions
in the A-MDR analyses. Numerous two-locus GxG interactions were significantly asso-
ciated with efficacy of MTX based on pOR, pRR, and pChi. We found that pChi flagged
the most GxG interactions as significantly associated with efficacy of MTX. After we
used the ReliefF algorithm to narrow down the list of candidate SNPs to 7, 15 pairs
GxG interactions were flagged as significant after FDR correction. Table 5 lists pOR,
pRR, and pChi along with 95% confidence intervals, unadjusted p-values, and FDR-
adjusted p-values for two-locus GxG interactions among 7 filtered SNPs. For the most
part, the three measures of GxG interactions (pOR, pRR, and pChi) yielded unadjusted
p-values that were in qualitative agreement. The epistasis-enriched network based on
the 15 significant two-locus GxG interactions from seven SNPs in five genes appears in
Figure 2A.
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Another goal of our A-MDR analysis was to integrate numerous significant GxG
interactions into a continuous epistasis enriched risk score for the prediction of which
patients would have active arthritis despite MTX treatment. A higher epistasis enriched
risk score would indicate that a patient carried more high-risk genotypic combinations
in loci with significant GxG interactions, and vice versa. To compare prediction accur-
acies based on the number of candidate SNPs as well as the presence or absence of ad-
justment for multiple comparisons, we generated epistasis enriched risk scores from 82
significant GxG interactions from 34 SNPs (Figure 2B).
Subjects with persistent active arthritis had significantly higher mean and median
epistasis enriched risk scores compared to subjects without active arthritis (p < 0.0001).
When 82 GxG interactions from 34 SNPs with unadjusted p-values < 0.0167 were used
to generate epistasis enriched risk scores (Figure 2B boxplot inset), these scores ranged
from 0 to 44. A higher risk score suggests that a subject is less likely to respond favor-
ably to MTX treatment. The ROC curve assessing the overall ability of the epistasis
enriched risk score to distinguish between subjects with active joints and subjects with-
out active joints had 85% area under the curve (p < 0.0001). (The 0.0167 cutoff for un-
adjusted p-values was chosen to maximize this area.) We correctly classify 82% of the
subjects if we predict that those with epistasis enriched risk scores above 11.5 have
active joints and that those with epistasis enriched risk scores below 11.5 do not have
persistent joint involvement.
Examination of the five genes in the 15-interaction model presented in Figure 2A
reveals a testable hypothesis for future studies. All genes fall within a pathway leading
to purine biosynthesis and adenosine formation: SLC25A32 transports folates from the
cytoplasm to mitochondria; MTHFD2 is a component of the mitochondrial folate path-
way that produces one-carbon donors in the form of formate (10-formyl-tetrahydrofo-
late) exclusively to support de novo purine biosynthesis; and ITPA, ATIC, and GART
are involved in purine biosynthesis. Thus, all genes map to a core pathway associated
Table 4 List of 34 SNPs from 18 candidate genes in the folate pathway
Gene RS# Gene RS#
ABCG2 rs7699188 GGH rs3758149
−15846A>C rs11545078
rs35252139 ITPA rs2295553
rs35229708 MTHFD1 rs2236225
rs55930652 MTHFD2 5nt ins/16nt del
ADORA2a rs2298383 rs56168672
rs3761422 rs12196
rs2267076 MTHFR rs1801133
rs2236624 rs1801131
ATIC rs2372536 rs2274976
rs12995526 MTR rs1805087
rs4673990 MTRR rs1801394
BHMT rs3733890 SHMT-1 rs1979277
DHFR 19 bp deletion SLC25A32 rs17803441
rs7387 SLCO1B1 Rs4149056
GART rs8971 SLC19A1 rs1051266
TSER rs34743033 TYMS rs11280056
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Table 5 Two-locus GxG interactions among 7 SNPs assessed by A-MDR
Two-locus
GxG Interactions
pOR p-value FDR pRR p-value FDR pChi p-value FDR
ATIC rs4673990+
MTHFD2 rs12196
3.9
(1.6–13.1)
0.001* 0.013* 1.9
(1.2-4.1)
0.001* 0.027* 6.1
(1.8-21.1)
<.001* 0.002*
ATIC rs4673990 +
MTHFD2
5nt ins/16nt del
3.7
(1.5-12.8)
0.001* 0.013* 1.8
(1.1-3.6)
0.003* 0.032* 6.0
(1.6-22.0)
<.001* 0.002*
MTHFD2 rs12196 +
GART rs8971
2.8
(1.1-8.8)
0.013* 0.069 1.6
(0.9-3.4)
0.016* 0.050 5.5
(1.3-20.7)
0.001* 0.009*
MTHFD2 5nt ins/16nt
del + GART rs8971
2.6
(1.0-7.9)
0.017* 0.069 1.5
(0.9-2.7)
0.017* 0.050 5.0
(1.1-20.6)
0.002* 0.011*
ATIC rs4673990 +
GART rs8971
2.5
(1.1-8.8)
0.027* 0.071 1.4
(0.9-2.4)
0.038* 0.088 4.7
(1.1-19.2)
0.009* 0.019*
ATIC rs2372536 +
MTHFD2
5nt ins/16nt del
2.5
(1.0-8.3)
0.017* 0.069 1.6
(1.0-3.6)
0.006* 0.041* 5.0
(1.1-17.6)
0.011* 0.020*
ATIC rs2372536 +
MTHFD2
rs12196
2.4
(0.9-8.0)
0.021* 0.069 1.4
(1.0-3.0)
0.033* 0.088 5.6
(1.2-18.3)
0.008* 0.019*
ATIC rs2372536 +
GART rs8971
2.2
(0.8-6.5)
0.032* 0.074 1.5
(0.9-2.8)
0.015* 0.050 4.5
(0.8-28.2)
0.012* 0.020*
SLC25A32 rs17803441 +
ITPA rs2295553
2.4
(0.8-7.5)
0.023* 0.069 1.6
(1.0-2.8)
0.013* 0.050 4.2
(0.8-17.9)
0.005* 0.019*
ATIC rs4673990 +
SLC25A32
rs17803441
2.3
(0.8-8.2)
0.039* 0.081 1.4
(0.8-2.2)
0.061 0.106 4.9
(0.9-30.9)
0.009* 0.019*
MTHFD2 rs12196 + ITPA
rs2295553
2.1
(0.9-7.1)
0.047* 0.090 1.4
(0.8-2.1)
0.065 0.106 4.2
(1.0-16.0)
0.025* 0.034*
ATIC rs4673990 + ITPA
rs2295553
2.3
(0.7-7.1)
0.074 0.101 1.4
(0.7-2.2)
0.076 0.106 3.7
(0.9-13.2)
0.045* 0.059
MTHFD2 rs12196 +
SLC25A32
rs17803441
2.2
(0.7-6.9)
0.060 0.097 1.4
(0.8-2.3)
0.067 0.106 5.2
(0.9-27.2)
0.012* 0.020*
ATIC rs2372536 +
SLC25A32
rs17803441
2.2
(0.7-6.1)
0.056 0.097 1.3
(0.9-2.7)
0.062 0.106 6.6
(0.9-37.9)
0.008* 0.019*
MTHFD2 5nt ins/16nt
del + MTHFD2 rs12196
2.0
(0.9-7.0)
0.074 0.101 1.3
(0.9-2.2)
0.088 0.115 5.2
(0.8-33.1)
0.008* 0.019*
MTHFD2 5nt ins/16nt
del +LC25A32 rs17803441
2.0
(0.6-5.9)
0.077 0.101 1.3
(0.9-3.3)
0.073 0.106 4.2
(0.7-25.5)
0.015* 0.023*
MTHFD2 5nt ins/16nt
del + ITPA rs2295553
1.9
(0.8-6.4)
0.114 0.139 1.3
(0.9-2.6)
0.129 0.160 3.9
(0.8-14.6)
0.076 0.094
ATIC rs2372536 + ITPA
rs2295553
1.9
(0.8-6.9)
0.119 0.139 1.3
(0.9-2.2)
0.182 0.201 3.9
(0.8-13.3)
0.091 0.101
GART rs8971 + ITPA
rs2295553
1.9
(0.8-8.9)
0.186 0.195 1.3
(0.9-3.6)
0.217 0.228 4.7
(0.8-16.1)
0.124 0.130
ATIC rs2372536 + ATIC
rs4673990
1.8
(0.7-5.3)
0.131 0.145 1.2
(0.8-2.0)
0.161 0.188 4.0
(0.7-23.3)
0.089 0.101
GART rs8971 + SLC25A32
rs17803441
1.7
(0.4-9.9)
0.227 0.227 1.2
(0.7-5.7)
0.296 0.296 3.5
(0.4-19.1)
0.156 0.156
(Three measures of GxG interactions [pOR, pRR, and pChi] along with 95% confidence intervals [CI] were obtained for
each two-locus GxG interaction. The p-value columns list unadjusted p-values, while the FDR columns list p-values after
adjustment for multiple comparisons. Significant GxG interactions, as judged by p-value or FDR less than 0.05, are
labeled with asterisks. The first GxG interaction in the table was the optimal two-locus GxG interactions identified by the
original MDR method with significant testing accuracy but insignificant CVC).
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with adenosine accumulation, which is considered to be a mechanism of action of
MTX that contributes to response in JIA and Rheumatoid Arthritis.
Discussion
In this work, we have proposed an Aggregated Multifactor Dimensionality Reduction
(A-MDR) model to elucidate complex and non-linear genetic associations contributing to
disease risk and variability in response to treatment. The proposed method is innovative in
three important ways: 1) a continuous GxG enriched risk score is generated to replace the
dichotomous risk factor in prediction of susceptibility to disorders; 2) new measures of
gene-gene interaction using pOR, pRR, and pChi along with p-values and confidence inter-
vals are proposed to detect and characterize multiple gene-gene interactions; and, 3) a radial
network is generated to depict patterns of epistasis. This approach allows for prediction on
not just a single interactive model, which is important given the growing appreciation in
human genetics for the accumulative impact of a large number of variants with low effect
size [28]. By pooling moderate and inter-related genetic contributors together, the A-MDR
model becomes robust and predictive of complex traits. In addition to GxG interactions,
the A-MDR can also be applied to model gene-environment interactions where environ-
mental risk factors such as smoking, alcohol consumption, exercise, and diet can be incor-
porated into multi-factorial models.
The original MDR model selects an optimal multi-factorial (SNP) combination for each
two-way, three-way or higher order interaction. When multiple genes function together
in a pathway, the original MDR is prone to overlook genes with weaker signals and lose
power for selecting one optimal GxG interaction in cross-validation. For the MTX data,
the optimal two-locus interaction detected by the original MDR among 7 candidate SNPs
was ATIC (rs4673990) + MTHFD2 (rs12196) with testing accuracy of 0.73 (p=0.0005).
However, there exist other pairs of interactions with comparable accuracy. As a result,
CVC, which measures the percentage of times that an optimal GxG interaction is selected
when splitting the training and validation sets randomly, was not significant (CVC=8/10,
p=0.2700). Our A-MDR analysis in Table 5 identified 15 pairs of two-locus interactions.
When multiple GxG interactions with bio-equivalent effects are involved in epistasis, the
original MDR will select an optimal model, by chance and lose some of the real pathway-
based signals. The recent extended MDR methods, including OR-MDR [17], LM-MDR
[18] and G-MDR [19], adopt the same strategy of selecting one optimal GxG interaction
as does the original MDR, which means they have the same limitations.
A continuous GxG enriched risk score is another major distinction between A-MDR and
all the majority of existing MDR models, in which a binary risk factor is utilized to predict
the outcome variable. For M-way interactions, the existing MDR models classify ~3M geno-
typic combinations as either high-risk or low-risk. A-MDR evolves from the traditional
MDR outputs to the predisposing risk scores and epistasis based network as shown in
Figure 2.
Another important result of the simulation experiments is the potential of A-MDR to
detect models that include genetic heterogeneity. Previous work with the original MDR
has shown that heterogeneity is disastrous when using MDR to detect interactions [26]
[29]. Because of the use of the continuous enrichment score, A-MDR is less impacted by
heterogeneity in the enclosed simulations. Further evaluation of this initial result with
expanded simulations and real data applications will be an important next step.
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We explore a radial network (Figure 2A) to depict patterns of epistasis. From the sys-
tems biology perspective, genetic variants might jointly impact the disease susceptibility
and response to treatment. The gene-gene interaction network reveals intriguing informa-
tion when interpreted in the context of what we know about the folate pathway and the
effect that MTX has upon the disruption of this pathway as it relates to arthritis. ATIC
and MTHFD2 were the two genes with the strongest interaction, and it is of interest to
note that the genes included in the model (Figure 2A) include a transporter involved in
folate uptake into mitochondria, SLC25A32, and the bifunctional methylenetetrahydrofo-
late dehydrogenase-cyclohydrolase MTHFD2, a key constituent of the mitochondrial fol-
ate pathway. The mitochondrial folate pathway is responsible for the generation of
formate (in the form of 10-formylTHF) specifically to support purine biosynthesis, repre-
sented by ATIC, GART, and ITPA. The anti-inflammatory effect of low-dose MTX used
to treat JIA and RA is thought to be due the anti-inflammatory effects of adenosine,
formed as a consequence of the inhibitory effects of MTX on amino-imidazole carboxa-
mide ribonucleotide (AICAR) transformylase (gene name, ATIC), which promotes the ac-
cumulation of AICAR ribotide, inhibiting adenosine deaminase and leading to a build up
of adenosine, a potent anti-inflammatory agent [30]. A disruption of this process may re-
sult in a decreased anti-inflammatory effect of the drug. Therefore, the combined effect of
SNPs in ATIC and MTHFD2 may indeed yield a more clinically apparent result by altering
the anti-inflammatory effects of methotrexate. There is a potential to apply the proposed
method to GWAS study by dissecting SNPs into pathways in order to detect GxG interac-
tions in GWAS pathways. The major computational challenges from the proposed
A-MDR and other approach in MDR framework are in the generation of p-values for
MDR. MDR permutation computing time is largely dependent on the dimension of data
sets. In other words, the computing time increases as the number of SNPs and/or the
number of subjects increases. Several works have been devoted to improve the efficiency
and shorten the computing time in MDR analysis in high-throughput data [5,31,32]. We
will defer interested readers to the corresponding citations for computing issues in high-
throughput MDR analysis. These computational limitations make our strategy appropriate
in large scale candidate gene studies, but may be limited in application to genome-wide
association studies until further improvements in computing speed are realized or very
large-scale computing resources are available.
In summary, bioinformatics challenges remain in detecting and modeling epistasis in
complex biological traits. We have developed a new A-MDR framework to interpret com-
plex genetic variation and have proposed predicting an outcome using a continuous risk
factor. Several other extensions and modifications of the original MDR have been pro-
posed in the literature. Incorporation of valuable features from other MDR extension
models into the A-MDR framework is worth further investigation. Prospective studies
and validation in independent samples are needed to assess reliability of the A-MDR
model’s predictive ability. Tools for statistical inference, including asymptotic distributions
of the proposed test statistics, need to be developed to save computing time and improve
reliability.
Appendix
Appendix I. Justification, 95% confidence intervals and permutation tests of pOR, pRR
and pChi.
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Since the predisposing risk factor (Table 1) is conditioned on the naïve Bayes classi-
fier, standard inference procedures based on normal or chi-square asymptotic distribu-
tions with 1 degree of freedom do not apply to the numerators in (1)-(3), which are the
unadjusted odds ratio (OR), relative risk (RR) and Chi-square statistics (Chi). As a
result, 95% confidence intervals of OR and RR are often greater than 1 under H0. To
address this issue, we propose pOR, pRR and pChi by taking the null distribution of
unadjusted statistics into account. Let x=pOR,pRR, or pChi, F(x) be the cumulative dis-
tribution function of the corresponding statistic under the alterative hypothesis (GxG
interaction present) F0(x),be the cumulative distribution function of the corresponding
statistic under the null hypothesis (GxG interaction absent) and F0
− 1(x) be the inverse
function of F0(x). The corrected pOR, pRR and pChi are then defined by xF10 F xð Þð Þ
. Under
H0, F(x)=F0(x), so pOR, pRR and pChi should equal xF10 F xð Þð Þ
¼ xF10 F0 xð Þð Þ ¼ 1. This adjust-
ment will ensure the insignificant GxG interactions to have 95% confidence interactions
cross 1 under Under H0. In this work, we evaluated pOR, pRR and pChi using a full
data set while these methods can also be evaluated under the cross validation scheme
typically used in MDR.
The functions F(x) and F0(x) can be estimated by the corresponding empirical distri-
bution function. Permutation is applied to estimate F0(x) by reshuffling the relationship
between SNPs and a phenotype, where SNPs for each individual in a system are main-
tained as a vector to preserve their correlation structure. For each permutation, we gen-
erated odds ratio (OR), relative risk (RR) and chi-square test statistic (Chi). Jackknife
re-sampling was applied to estimate F(x) by generating random subsets of data, where
80% to 90% of subjects were randomly selected. SNPs and the phenotype from each
subject are maintained as a vector to preserve the association between SNPs and the
phenotype. Denote the OR, RR and Chi statistic from permutation or re-sampling as
x1,x2,. . .xB where B is the number of permutation or resampling. The null distribution
function F0(x) and F(x) can be estimated by B1
XB
i¼1I xi≤xf g . The 95% confidence inter-
val pOR, pRR and pChi can be obtained by resampling. Denote the pOR, pRR and pChi
statistics from resampling or permutation as z1,z2. . .,zB then the 95% confidence inter-
val pOR, pRR and pChi is the interval from 2.5 to 97.5 percentile of z1,z2. . .,zB from
resampling. The p-value for pOR, pRR and pChi for the ith GxG interaction, denoted
by Pvaluei, will be calculated by the permutation testing, i.e. Pvaluei ¼ B1
XB
i¼1I z<zif g
where z1,z2. . .,zB are calculated from permutation samples and z is the pOR, pRR and
pChi statistic calculated from the current data.
Competing interests
There are no competing interests to this work.
Authors’ contributions
HD conceived of the study. RC and AMR aided in study design and statistical method. HD performed the simulations
and data analysis. MB and SL performed the clinical data collection, genotyping and interpretation of case study
findings. All authors contributed to the manuscript writing. All authors read and approved the final manuscript.
Acknowledgements
This work is supported for collaboration between HD and AMR by Bursary Award of the 1st Short Course on Statistical
Genetics and Genomics from University of Alabama at Birmingham from the National Institute of Health
R25GM093044 (PI: Tiwari). Special thanks to two reviewers for instructive comments to help us improve the
manuscript.
Dai et al. BioData Mining 2013, 6:1 Page 14 of 16
http://www.biodatamining.org/content/6/1/1
Author details
1Research Development and Clinical Investigation, Children’s Mercy Hospital, Kansas City, MO 64108, USA. 2Division of
Clinical Pharmacology and Medical Toxicology, Department of Pediatrics, Children’s Mercy Hospital, Kansas City, MO
64108, USA. 3Department of Statistics, University of Kentucky, Lexington, KY 40506, USA. 4Bioinformatics Research
Center, Department of Statistics, North Carolina State University, Raleigh, NC 27695, USA.
Received: 4 September 2012 Accepted: 21 December 2012
Published: 8 January 2013
References
1. Moore JH: Detecting, characterizing, and interpreting nonlinear gene-gene interactions using multifactor
dimensionality reduction. Adv Genet 2010, 72:101–116.
2. Cantor RM, Lange K, Sinsheimer JS: Prioritizing GWAS results: a review of statistical methods and
recommendations for their application. Am J Hum Genet 2009, 86(1):6–22.
3. Ritchie MD, Hahn LW, Roodi N, Bailey LR, Dupont WD, Parl FF, Moore JH: Multifactor-dimensionality reduction
reveals high-order interactions among estrogen-metabolism genes in sporadic breast cancer. Am J Hum
Genet 2001, 69(1):138–147.
4. Hahn LW, Ritchie MD, Moore JH: Multifactor dimensionality reduction software for detecting gene-gene and
gene-environment interactions. Bioinformatics 2003, 19(3):376–382.
5. Bush WS, Dudek SM, Ritchie MD: Parallel multifactor dimensionality reduction: a tool for the large-scale
analysis of gene-gene interactions. Bioinformatics 2006, 22(17):2173–2174.
6. Winham SJ, Motsinger-Reif AA: An R package implementation of multifactor dimensionality reduction. BioData
Min 2011, 4(1):24.
7. Robnik-Siknja M, Kononeko I: Theoretical and empirical analysis of RelifF and RReliefF. Mach Learn 2003, 53:23–69.
8. Dai H, Bhandary M, Becker ML, Leeder SJ, Gaedigk R, Motsinger-Reif AA: Global tests of p-values for multifactor
dimensionality reduction models in selection of optimal number of target genes. BioData Min 2012, 5(1):3.
9. Motsinger AA, Ritchie MD: The effect of reduction in cross-validation intervals on the performance of
multifactor dimensionality reduction. Genet Epidemiol 2006, 30(6):546–555.
10. Hastie T, Tibshirani R, Friedman J: The Elements of Statistical Learning: Data Mining, Inference, and Predication. New
York, USA: Springer; 2001.
11. Good P: Permutation Tests: A Practical Guide to Resampling Methods for Testing Hypotheses. New York, USA:
Springer; 2000.
12. Moore JH, Williams SM: New strategies for identifying gene-gene interactions in hypertension. Ann Med 2002,
34(2):88–95.
13. Andrew AS, Karagas MR, Nelson HH, Guarrera S, Polidoro S, Gamberini S, Sacerdote C, Moore JH, Kelsey KT,
Demidenko E, et al: DNA repair polymorphisms modify bladder cancer risk: a multi-factor analytic strategy.
Hum Hered 2008, 65(2):105–118.
14. Cho YM, Ritchie MD, Moore JH, Park JY, Lee KU, Shin HD, Lee HK, Park KS: Multifactor-dimensionality reduction
shows a two-locus interaction associated with Type 2 diabetes mellitus. Diabetologia 2004, 47(3):549–554.
15. Becker ML, Gaedigk R, van Haandel L, Thomas B, Lasky A, Hoeltzel M, Dai H, Stobaugh J, Leeder JS: The effect of
genotype on methotrexate polyglutamate variability in juvenile idiopathic arthritis and association with drug
response. Arthritis Rheum 2011, 63(1):276–285.
16. Dervieux T, Wessels JA, van der Straaten T, Penrod N, Moore JH, Guchelaar HJ, Kremer JM: Gene-gene
interactions in folate and adenosine biosynthesis pathways affect methotrexate efficacy and tolerability in
rheumatoid arthritis. Pharmacogenet Genomics 2009, 19(12):935–944.
17. Chung Y, Lee SY, Elston RC, Park T: Odds ratio based multifactor-dimensionality reduction method for
detecting gene-gene interactions. Bioinformatics (Oxford England) 2007, 23(1):71–76.
18. Lee SY, Chung Y, Elston RC, Kim Y, Park T: Log-linear model-based multifactor dimensionality reduction
method to detect gene gene interactions. Bioinformatics (Oxford England) 2007, 23(19):2589–2595.
19. Lou XY, Chen GB, Yan L, Ma JZ, Zhu J, Elston RC, Li MD: A generalized combinatorial approach for detecting
gene-by-gene and gene-by-environment interactions with application to nicotine dependence. Am J Hum
Genet 2007, 80(6):1125–1137.
20. Velez DR, White BC, Motsinger AA, Bush WS, Ritchie MD, Williams SM, Moore JH: A balanced accuracy function
for epistasis modeling in imbalanced datasets using multifactor dimensionality reduction. Genet Epidemiol
2007, 31(4):306–315.
21. Calle ML, Urrea V, Vellalta G, Malats N, Steen KV: Improving strategies for detecting genetic patterns of disease
susceptibility in association studies. Stat Med 2008, 27(30):6532–6546.
22. Bush WS, Edwards TL, Dudek SM, McKinney BA, Ritchie MD: Alternative contingency table measures improve
the power and detection of multifactor dimensionality reduction. BMC Bioinformatics 2008, 9:238.
23. Lou XY, Chen GB, Yan L, Ma JZ, Mangold JE, Zhu J, Elston RC, Li MD: A combinatorial approach to detecting
gene-gene and gene-environment interactions in family studies. Am J Hum Genet 2008, 83(4):457–467.
24. Mei H, Cuccaro ML, Martin ER: Multifactor dimensionality reduction-phenomics: a novel method to capture
genetic heterogeneity with use of phenotypic variables. Am J Hum Genet 2007, 81(6):1251–1261.
25. Moore JH, Gilbert JC, Tsai CT, Chiang FT, Holden T, Barney N, White BC: A flexible computational framework for
detecting, characterizing, and interpreting statistical patterns of epistasis in genetic studies of human
disease susceptibility. J Theor Biol 2006, 241(2):252–261.
26. Ritchie MD, Hahn LW, Moore JH: Power of multifactor dimensionality reduction for detecting gene-gene
interactions in the presence of genotyping error, missing data, phenocopy, and genetic heterogeneity.
Genet Epidemiol 2003, 24(2):150–157.
27. Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A: Preliminary definition of improvement in
juvenile arthritis. Arthritis Rheum 1997, 40(7):1202–1209.
Dai et al. BioData Mining 2013, 6:1 Page 15 of 16
http://www.biodatamining.org/content/6/1/1
28. Yang J, Manolio TA, Pasquale LR, Boerwinkle E, Caporaso N, Cunningham JM, de Andrade M, Feenstra B, Feingold
E, Hayes MG, et al: Genome partitioning of genetic variation for complex traits using common SNPs. Nat Genet
2011, 43(6):519–525.
29. Ritchie MD, Edwards TL, Fanelli TJ, Motsinger AA: Genetic heterogeneity is not as threatening as you might
think. Genet Epidemiol 2007, 31(7):797–800.
30. Cronstein BN, Naime D, Ostad E: The antiinflammatory mechanism of methotrexate. Increased adenosine
release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J Clin Invest
1993, 92(6):2675–2682.
31. Oki NO, Motsinger-Reif AA: Multifactor dimensionality reduction as a filter-based approach for genome wide
association studies. Front Genet 2011, 2:80.
32. Yang C, Wan X, He Z, Yang Q, Xue H, Yu W: The choice of null distributions for detecting gene-gene
interactions in genome-wide association studies. BMC Bioinformatics 2011, 12(Suppl 1):S26.
doi:10.1186/1756-0381-6-1
Cite this article as: Dai et al.: Risk score modeling of multiple gene to gene interactions using aggregated-
multifactor dimensionality reduction. BioData Mining 2013 6:1.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Dai et al. BioData Mining 2013, 6:1 Page 16 of 16
http://www.biodatamining.org/content/6/1/1
